<DOC>
	<DOC>NCT01257412</DOC>
	<brief_summary>This study intends to compare the efficacy and safety of dapagliflozin versus placebo in treatment-naïve subjects with type 2 diabetes who have inadequate glycaemic control with diet and exercise alone.</brief_summary>
	<brief_title>Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Provision of informed consent before participating in the study Diagnosed with type 2 diabetes (high blood sugar); HbA1c ≥ 7.2% and ≤10.0% Subjects should be drug naïve Women of childbearing potential who comply to use an adequate method of contraception to avoid pregnancy throughout the study &amp; who have a negative serum or urine pregnancy test Subjects received Insulin therapy within one year of enrollment Subjects who have severe uncontrolled hypertension Subjects who have history of unstable or rapidly progressing renal disease Subjects who have severe liver disease Subjects who receiving treatment for Human immunodeficiency virus (HIV)</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Phase III</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>inadequate glycaemic control</keyword>
</DOC>